Evidence map›Paper›PMID 41883354›Full record

ArticleDrug, healthcare and patient safety2026

Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan.

Akina Takami, Gen Terashima, Yuichi Shiotsuki, Koki Yamashita, Ataru Igarashi

Abstract read
In one paragraph

Article in Drug, healthcare and patient safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Akina TakamiDepartment of Health Policy and Public Health, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan.ORCID 0009-0004-3289-822X
Gen TerashimaReal World Evidence Division, JMDC, Inc., Tokyo, Japan.ORCID 0000-0002-6804-5585
Yuichi ShiotsukiReal World Evidence Division, JMDC, Inc., Tokyo, Japan.ORCID 0009-0005-1091-8311
Koki YamashitaMaxwell International, Inc., Chiba, Japan.ORCID 0009-0005-3187-0900
Ataru IgarashiDepartment of Health Policy and Public Health, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan.ORCID 0000-0001-6307-6916

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Long-term use of proton pump inhibitors (PPIs) requires careful observation with endoscopy in Japan. However, there are no studies examining whether monitoring is being properly carried out in clinical practice. Thus, we investigate the usage of PPIs by the presence or absence of endoscopic monitoring using a claims database. Methods: This study was a retrospective observational cohort study using the nationwide claims database. We obtained data of patients diagnosed with GERD (excluding suspected cases) between April 2014 and March 2024. Inclusion criteria were patients aged 18 years or older, continuously prescribed drugs of interest (omeprazole, lansoprazole, rabeprazole, esomeprazole, and vonoprazan) for 8 weeks or more. To assess the duration of prescriptions over a one-year period, the medication possession ratio (MPR) showing the prescription days per year ratio was examined. MPR was compared between patients who underwent endoscopy [endoscopy(+) group] and those who did not [endoscopy(-) group] during the follow-up period of 12 months. Results: A total of 398,253 patients [endoscopy(+) group: 142,653; endoscopy(-) group: 255,600] were included in the analysis. The median MPR was 0.534 in the endoscopy(+) group and 0.805 in the endoscopy(-) group; MPR was significantly higher in the endoscopy(-) group (p < 0.0001). Conclusion: These findings revealed that the long-term administration of PPIs without monitoring esophageal mucosa by endoscopy in patients with GERD is a common practice in Japan. However, compliance with the package inserts suggesting adequate observation, including periodic endoscopic examinations, should be highlighted to ensure safety.

Indexed as

gastroesophageal reflux diseasepost-marketingproton pump inhibitorreal-world datasafety

Identifiers

PMID41883354
PMCPMC13012140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.